The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection on antiretroviral therapy (ART).
The scope includes: (i) guidance on the initiation of ART in those previously naïve to therapy; (ii) support of people living with HIV (PLWH) on treatment; (iii) management of individuals experiencing virological failure; and (iv) recommendations in specific populations where other factors need to be taken into consideration.
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens.
2022 interim BHIVA guidance on LA-CAB/RPV
2022 interim BHIVA guidance on long-acting cabotegravir/rilpivirine (LA-CAB/RPV) for antiretroviral therapy
2019 interim statement on two-drug regimens
BHIVA treatment guidelines: 2019 interim statement on two-drug regimens
Appendices for these guidelines
Appendix 1 Summary of the modified GRADE system
Appendix 2 PICO questions and search strategies
Appendix 3 Grade tables
Appendix 4 Food considerations for antiretrovirals
Appendix 5 Considerations for antiretrovirals in renal impairment
Consultation comments (2015)
Comments received by the BHIVA Secretariat during the public consultation process
Please note: The non-technical summary is less detailed than the full guideline and if you are reading this because it is relevant to your own healthcare, please do discuss any concerns or questions with your healthcare professionals.
L Waters (Chair), N Ahmed, B Angus, M Boffito, M Bower, D Churchill, D Dunn, S Edwards, C Emerson, S Fidler, M Fisher †, R Horne, S Khoo, C Leen, N Mackie, N Marshall, F Monteiro, M Nelson, C Orkin, A Palfreeman, S Pett, A Phillips, F Post, A Pozniak, I Reeves, C Sabin, R Trevelion, J Walsh, E Wilkins, I Williams, A Winston
† Professor Martin Fisher died in April 2015 - he made a significant contribution to these, many other guidelines and our speciality as a whole - he is greatly missed.
The guidelines were peer reviewed by Professor Jose Arribas, La Paz Hospital and Autonoma University School of Medicine Madrid, Spain, Professor Francois Raffi, University Hospital, Nantes, France, and Professor Linos Vandekerckhove, University Hospital Ghent, Belgium.